Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second IVIg dose in Guillain-Barré syndrome patients with poor prognosis
NL-OMON24041Suspended
- Sponsor
- Erasmus MC
- Start
- Mar 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of immune globulin in Guillain-Barré syndrome (GBS) (2 arms), sponsored by Erasmus MC. Primary endpoint: Functional outcome at 4 weeks. Started Mar 2012; status: suspended.
02
Drugs
immune globulin
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NL-OMON24041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24041.